Cleerly Welcomes New Executive Team Members

There’s a trio of new faces within Cleerly’s senior management circle.

The company recently appointed industry veteran Steven Borg as chief technology officer and David McGovern as vice president of Marketing, and promoted Jim Hartman to chief commercial officer . 
 
“We are thrilled to welcome Steven and David, as well as congratulate Jim on his well-deserved promotion. Their skills and expertise will undoubtedly strengthen Cleerly’s position as an industry leader and drive our mission to revolutionize cardiovascular care,” Cleerly Founder/CEO Dr. James Min said. “With the addition of Steven and David, and the promotion of Jim, we are confident that our clinical, commercial, and technical teams will further enhance health literacy for everyone in the coronary care pathway.”
 
Borg is a technology industry leader and innovator with 23 years of experience driving organizational transformation. He previously served as chief technology officer at 3motion.ai and senior director of Health Data and AI at Microsoft. Borg’s expertise in artificial intelligence and his innovative technical vision will be instrumental as he leads Cleerly’s technology initiatives, according to the company.
 
McGovern has more than 30 years of diverse marketing and commercial leadership experience in the life science and healthcare industry. His previous roles include senior vice president of Marketing at SomaLogic and leadership positions at Pfizer, Change Healthcare, and several multinational biotechnology organizations. McGovern’s extensive experience in driving innovative healthcare software, analytics, and service solutions will be invaluable in elevating Cleerly’s marketing strategy.
 
Hartman’s leadership and strategic vision have been instrumental in accelerating sales and expanding Cleerly’s market presence since joining in 2021 as chief revenue officer. With his promotion to chief commercial officer, Hartman will continue to leverage his extensive experience in developing high-performing sales teams and executing strategic business plans to further drive Cleerly’s commercial success. 
 
Cleerly is on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its U.S. Food and Drug Administration-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive computed tomography imaging. Cleerly’s approach is grounded in science, based on millions of images from more than 40,000 patients. Led by a clinical and technical team, Cleerly enhances health literacy for each stakeholder in the coronary care pathway.